Cargando…

Phase-specific and lifetime costs of cancer care in Ontario, Canada

BACKGROUND: Cancer is a major public health issue and represents a significant economic burden to health care systems worldwide. The objective of this analysis was to estimate phase-specific, 5-year and lifetime net costs for the 21 most prevalent cancer sites, and remaining tumour sites combined, i...

Descripción completa

Detalles Bibliográficos
Autores principales: de Oliveira, Claire, Pataky, Reka, Bremner, Karen E., Rangrej, Jagadish, Chan, Kelvin K. W., Cheung, Winson Y., Hoch, Jeffrey S., Peacock, Stuart, Krahn, Murray D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070134/
https://www.ncbi.nlm.nih.gov/pubmed/27756310
http://dx.doi.org/10.1186/s12885-016-2835-7
_version_ 1782461078941204480
author de Oliveira, Claire
Pataky, Reka
Bremner, Karen E.
Rangrej, Jagadish
Chan, Kelvin K. W.
Cheung, Winson Y.
Hoch, Jeffrey S.
Peacock, Stuart
Krahn, Murray D.
author_facet de Oliveira, Claire
Pataky, Reka
Bremner, Karen E.
Rangrej, Jagadish
Chan, Kelvin K. W.
Cheung, Winson Y.
Hoch, Jeffrey S.
Peacock, Stuart
Krahn, Murray D.
author_sort de Oliveira, Claire
collection PubMed
description BACKGROUND: Cancer is a major public health issue and represents a significant economic burden to health care systems worldwide. The objective of this analysis was to estimate phase-specific, 5-year and lifetime net costs for the 21 most prevalent cancer sites, and remaining tumour sites combined, in Ontario, Canada. METHODS: We selected all adult patients diagnosed with a primary cancer between 1997 and 2007, with valid ICD-O site and histology codes, and who survived 30 days or more after diagnosis, from the Ontario Cancer Registry (N = 394,092). Patients were linked to treatment data from Cancer Care Ontario and administrative health care databases at the Institute for Clinical and Evaluative Sciences. Net costs (i.e., cost difference between patients and matched non-cancer control subjects) were estimated by phase of care and sex, and used to estimate 5-year and lifetime costs. RESULTS: Mean net costs of care (2009 CAD) were highest in the initial (6 months post-diagnosis) and terminal (12 months pre-death) phases, and lowest in the (3 months) pre-diagnosis and continuing phases of care. Phase-specific net costs were generally lowest for melanoma and highest for brain cancer. Mean 5-year net costs varied from less than $25,000 for melanoma, thyroid and testicular cancers to more than $60,000 for multiple myeloma and leukemia. Lifetime costs ranged from less than $55,000 for lung and liver cancers to over $110,000 for leukemia, multiple myeloma, lymphoma and breast cancer. CONCLUSIONS: Costs of cancer care are substantial and vary by cancer site, phase of care and time horizon analyzed. These cost estimates are valuable to decision makers to understand the economic burden of cancer care and may be useful inputs to researchers undertaking cancer-related economic evaluations. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-016-2835-7) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5070134
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-50701342016-10-24 Phase-specific and lifetime costs of cancer care in Ontario, Canada de Oliveira, Claire Pataky, Reka Bremner, Karen E. Rangrej, Jagadish Chan, Kelvin K. W. Cheung, Winson Y. Hoch, Jeffrey S. Peacock, Stuart Krahn, Murray D. BMC Cancer Research Article BACKGROUND: Cancer is a major public health issue and represents a significant economic burden to health care systems worldwide. The objective of this analysis was to estimate phase-specific, 5-year and lifetime net costs for the 21 most prevalent cancer sites, and remaining tumour sites combined, in Ontario, Canada. METHODS: We selected all adult patients diagnosed with a primary cancer between 1997 and 2007, with valid ICD-O site and histology codes, and who survived 30 days or more after diagnosis, from the Ontario Cancer Registry (N = 394,092). Patients were linked to treatment data from Cancer Care Ontario and administrative health care databases at the Institute for Clinical and Evaluative Sciences. Net costs (i.e., cost difference between patients and matched non-cancer control subjects) were estimated by phase of care and sex, and used to estimate 5-year and lifetime costs. RESULTS: Mean net costs of care (2009 CAD) were highest in the initial (6 months post-diagnosis) and terminal (12 months pre-death) phases, and lowest in the (3 months) pre-diagnosis and continuing phases of care. Phase-specific net costs were generally lowest for melanoma and highest for brain cancer. Mean 5-year net costs varied from less than $25,000 for melanoma, thyroid and testicular cancers to more than $60,000 for multiple myeloma and leukemia. Lifetime costs ranged from less than $55,000 for lung and liver cancers to over $110,000 for leukemia, multiple myeloma, lymphoma and breast cancer. CONCLUSIONS: Costs of cancer care are substantial and vary by cancer site, phase of care and time horizon analyzed. These cost estimates are valuable to decision makers to understand the economic burden of cancer care and may be useful inputs to researchers undertaking cancer-related economic evaluations. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-016-2835-7) contains supplementary material, which is available to authorized users. BioMed Central 2016-10-18 /pmc/articles/PMC5070134/ /pubmed/27756310 http://dx.doi.org/10.1186/s12885-016-2835-7 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
de Oliveira, Claire
Pataky, Reka
Bremner, Karen E.
Rangrej, Jagadish
Chan, Kelvin K. W.
Cheung, Winson Y.
Hoch, Jeffrey S.
Peacock, Stuart
Krahn, Murray D.
Phase-specific and lifetime costs of cancer care in Ontario, Canada
title Phase-specific and lifetime costs of cancer care in Ontario, Canada
title_full Phase-specific and lifetime costs of cancer care in Ontario, Canada
title_fullStr Phase-specific and lifetime costs of cancer care in Ontario, Canada
title_full_unstemmed Phase-specific and lifetime costs of cancer care in Ontario, Canada
title_short Phase-specific and lifetime costs of cancer care in Ontario, Canada
title_sort phase-specific and lifetime costs of cancer care in ontario, canada
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070134/
https://www.ncbi.nlm.nih.gov/pubmed/27756310
http://dx.doi.org/10.1186/s12885-016-2835-7
work_keys_str_mv AT deoliveiraclaire phasespecificandlifetimecostsofcancercareinontariocanada
AT patakyreka phasespecificandlifetimecostsofcancercareinontariocanada
AT bremnerkarene phasespecificandlifetimecostsofcancercareinontariocanada
AT rangrejjagadish phasespecificandlifetimecostsofcancercareinontariocanada
AT chankelvinkw phasespecificandlifetimecostsofcancercareinontariocanada
AT cheungwinsony phasespecificandlifetimecostsofcancercareinontariocanada
AT hochjeffreys phasespecificandlifetimecostsofcancercareinontariocanada
AT peacockstuart phasespecificandlifetimecostsofcancercareinontariocanada
AT krahnmurrayd phasespecificandlifetimecostsofcancercareinontariocanada